Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s437, 2024. DOI: 10.25251/skin.8.supp.437. Disponível em: https://skin.dermsquared.com/skin/article/view/3114. Acesso em: 19 oct. 2025.